ELAVL1 and ovarian carcinoma: Increase in HuR was found to correlate with improved response to treatment with adjuvant gemcitabine in pancreatic cancer; in contrast, HuR expression was shown to play a role in paclitaxel resistance in ovarian cancer [41-43].